A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
Phase of Trial: Phase IV
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Jul 2017 Planned End Date changed from 31 Aug 2017 to 2 Oct 2017.
- 12 Jul 2017 Planned primary completion date changed from 31 Aug 2017 to 2 Oct 2017.
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.